“Durability of DLQI Improvements Among Patients With Moderate to Severe Plaque Psoriasis Treated With Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)”. 2021. SKIN The Journal of Cutaneous Medicine 5 (1): s19. https://doi.org/10.25251/skin.5.supp.19.